新型取代苯并咪唑化合物作为用于治疗纤维化疾病，特别是特发性肺纤维化的TLR9抑制剂
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
Abstract
Provided herein are novel substituted benzimidazole compounds as TLR9 inhibitors, pharmaceutical compositions, use of such compounds in treating fibrotic diseases, particularly idiopathic pulmonary fibrosis, and processes for preparing such compounds.
摘要
本文提供了作为TLR9抑制剂的新型取代苯并咪唑化合物、药物组合物、此类化合物在治疗纤维化疾病（特别是特发性肺纤维化）中的用途以及制备此类化合物的方法。
相似文献
1
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
2
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
3
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
4
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12.
5
Ambulatory Oxygen for Pulmonary Fibrosis (OxyPuF): a randomised controlled trial and acceptability study.
Health Technol Assess. 2025 Jul 2:1-33. doi: 10.3310/TWKS4194.
6
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
7
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
8
Novel Heteroaryl Fluoroalkenes as DGK Inhibitors for Treating Cancer, Particularly Metastatic Melanoma.
ACS Med Chem Lett. 2024 Aug 22;15(9):1433-1434. doi: 10.1021/acsmedchemlett.4c00409. eCollection 2024 Sep 12.
9
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
10
Novel Imidazopyridine and Imidazopyridazine Derivatives as DGAT2 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Jul 3;15(8):1180-1181. doi: 10.1021/acsmedchemlett.4c00286. eCollection 2024 Aug 8.
本文引用的文献
1
Interactions between toll-like receptors signaling pathway and gut microbiota in host homeostasis.
Immun Inflamm Dis. 2024 Jul;12(7):e1356. doi: 10.1002/iid3.1356.
2
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation.
J Hepatol. 2024 Nov;81(5):895-910. doi: 10.1016/j.jhep.2024.06.016. Epub 2024 Jun 20.
3
Toll-like receptors in health and disease.
MedComm (2020). 2024 Apr 29;5(5):e549. doi: 10.1002/mco2.549. eCollection 2024 May.
4
Toll-like receptor signalling as a cannabinoid target.
Biochem Pharmacol. 2024 Apr;222:116082. doi: 10.1016/j.bcp.2024.116082. Epub 2024 Mar 2.
5
The role of Toll-like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management.
Med Res Rev. 2024 May;44(3):1267-1325. doi: 10.1002/med.22012. Epub 2024 Jan 16.
6
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
ACS Med Chem Lett. 2023 Apr 20;14(5):549-550. doi: 10.1021/acsmedchemlett.3c00131. eCollection 2023 May 11.
Zotero 插件